What is the appropriate treatment plan for a HLA‑B27‑positive patient with predominantly enthesitis?

Treatment of HLA-B27-Positive Patients with Predominantly Enthesitis

For HLA-B27-positive patients with predominantly enthesitis, initiate NSAIDs as first-line therapy; if enthesitis persists despite NSAIDs or local glucocorticoid injections, advance directly to biologic therapy (TNF inhibitor, IL-17 inhibitor, or IL-12/23 inhibitor), as conventional synthetic DMARDs are ineffective for enthesitis. 1

First-Line Management

• NSAIDs remain the cornerstone initial therapy for enthesitis in spondyloarthritis patients 2, 3
• Continuous NSAID use is recommended for active disease rather than on-demand dosing 2
• NSAIDs should be trialed at adequate doses and duration before escalating therapy 1

Local Glucocorticoid Injections

• For active peripheral enthesitis with stable axial disease failing NSAIDs, conditionally recommend local glucocorticoid injections 2, 3
• Injections should be performed in experienced specialist centers, preferably under imaging guidance (ultrasound or CT) to maximize accuracy 3
• Critical safety warning: Avoid peritendinous injections of Achilles, patellar, and quadriceps tendons due to documented tendon rupture risk 2, 3
• Local injections provide modest symptom reduction but are a temporizing measure, not definitive treatment 3

Biologic Therapy Escalation

When to advance to biologics:

• Unequivocal enthesitis with insufficient response to NSAIDs 1
• Insufficient response to or contraindication to local glucocorticoid injections 1
• The term "unequivocal" emphasizes true inflammation rather than trigger-point pain from widespread pain syndromes 1

Biologic selection for enthesitis:

• All biologics (TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors) demonstrate similar efficacy for enthesitis 1
• The 2020 EULAR guidelines removed the previous preference for TNF inhibitors, recognizing equivalent efficacy across biologic classes 1
• For ankylosing spondylitis with active disease despite NSAIDs, TNF inhibitors are strongly recommended over no treatment (high-quality evidence) 2
• Secukinumab or ixekizumab (IL-17 inhibitors) are also strongly recommended over no treatment (high-quality evidence) 2

What NOT to Do

• Do not use conventional synthetic DMARDs (methotrexate, sulfasalazine) as monotherapy for enthesitis—they are ineffective for this manifestation 1
  • However, research shows methotrexate is commonly prescribed in ERA cohorts (77.4% in one study), though 77.9% ultimately required anti-TNF therapy 4
• Strongly recommend against systemic glucocorticoids for axial spondyloarthritis per ACR/SAA/SPARTAN 2019 guidelines (very low-quality evidence, substantial harms) 2, 3
• Do not delay biologic initiation once NSAIDs and local measures have failed 1

Clinical Considerations for HLA-B27-Positive Patients

HLA-B27 positivity confers distinct disease characteristics:

• Higher inflammatory markers at diagnosis 5
• Greater disease activity throughout follow-up 5
• Increased likelihood of sacroiliitis development (probabilities of 0.364 at 1 year, 0.578 at 5 years) 4
• Male predominance (87-89% in cohort studies) 5, 4
• Higher utilization of bridging systemic corticosteroids (60.5% vs. 14.3% in HLA-B27-negative patients) and anti-TNF therapy (39.5% vs. 9.5%) 5

Predictors of requiring biologic therapy:

• Longer duration to diagnosis 4
• Methotrexate use (paradoxically predicts subsequent need for anti-TNF, as it fails in enthesitis) 4
• Among methotrexate-treated sacroiliitis patients, 85.3% failed and required anti-TNF 4

Physical Therapy

• Strongly recommend physical therapy over no physical therapy (moderate-quality evidence) 2
• Conditionally recommend active/supervised exercise over passive interventions (massage, ultrasound, heat) 2
• Physical therapy should be initiated alongside pharmacologic management 2

Common Pitfalls to Avoid

• Do not conflate entheseal pain with widespread pain syndromes—clinical examination should assess the number and asymmetrical pattern of painful entheses plus clinical swelling to distinguish true enthesitis 1
• Sonography or MRI can confirm enthesitis but are not mandatory; clinical examination should suffice 1
• Do not extrapolate rheumatoid arthritis treatment algorithms to spondyloarthritis—the pathophysiology and drug responsiveness differ fundamentally 3
• Do not use short-term systemic corticosteroids as a bridge while awaiting biologic initiation—insufficient evidence supports any benefit 3